» Articles » PMID: 34475865

Synbiotics Containing Nanoprebiotics: A Novel Therapeutic Strategy to Restore Gut Dysbiosis

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2021 Sep 3
PMID 34475865
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

A new formulation, nanoprebiotics [e.g., phthalyl pullulan nanoparticles (PPNs)], was demonstrated to enhance the antimicrobial activity of probiotics [e.g., (LP)] through intracellular stimulation better than that by backbone prebiotics, which are commonly used. In this study, we aimed to investigate whether this combination would exert distinct effects as synbiotics . Synbiotics combinations of LP, pullulan, and PPNs were used as experimental treatments in a dysbiosis-induced murine model, and their restorative effect was assessed using pathogen K99 challenge. Our results showed that the infection was suppressed markedly in the experimental group fed with synbiotics containing PPNs. In addition, the decrease in serum endotoxin level after synbiotics treatment suggested the reinforcement of the gut barrier. Comparison of treatment groups, including a normal control group, showed that synbiotics containing PPNs increased microbial diversity, which is a representative parameter of healthy status. Furthermore, distinct from probiotics treatment alone, synbiotics showed additive effects of enrichment of several well-known beneficial bacteria such as , and other butyrate-producing bacteria including . Collectively, our results indicate that synbiotics containing PPNs are effective at restoring gut dysbiosis, suppressing pathogenic infection, and increasing microbial diversity, suggesting that synbiotics with nanoprebiotics have the potential to be a novel strategy for ameliorating gut dysbiosis and infectious diseases.

Citing Articles

Pullulan nanoparticles inhibit the pathogenicity of by regulating hypha-related gene expression.

Hong S, Kim S, Chung C, Yun C, Lee J, Cho C Microbiol Spectr. 2024; :e0104824.

PMID: 39540747 PMC: 11619324. DOI: 10.1128/spectrum.01048-24.


Cross-feeding of bifidobacteria promotes intestinal homeostasis: a lifelong perspective on the host health.

Xiao M, Zhang C, Duan H, Narbad A, Zhao J, Chen W NPJ Biofilms Microbiomes. 2024; 10(1):47.

PMID: 38898089 PMC: 11186840. DOI: 10.1038/s41522-024-00524-6.

References
1.
Moludi J, Maleki V, Jafari-Vayghyan H, Vaghef-Mehrabany E, Alizadeh M . Metabolic endotoxemia and cardiovascular disease: A systematic review about potential roles of prebiotics and probiotics. Clin Exp Pharmacol Physiol. 2020; 47(6):927-939. DOI: 10.1111/1440-1681.13250. View

2.
Bhat M, Sowmya K, Kapila S, Kapila R . Escherichia coli K12: An evolving opportunistic commensal gut microbe distorts barrier integrity in human intestinal cells. Microb Pathog. 2019; 133:103545. DOI: 10.1016/j.micpath.2019.103545. View

3.
Ai D, Pan H, Li X, Gao Y, Liu G, Xia L . Identifying Gut Microbiota Associated With Colorectal Cancer Using a Zero-Inflated Lognormal Model. Front Microbiol. 2019; 10:826. PMC: 6491826. DOI: 10.3389/fmicb.2019.00826. View

4.
Davin-Regli A, Lavigne J, Pages J . spp.: Update on Taxonomy, Clinical Aspects, and Emerging Antimicrobial Resistance. Clin Microbiol Rev. 2019; 32(4). PMC: 6750132. DOI: 10.1128/CMR.00002-19. View

5.
Kim W, Han G, Hong L, Kang S, Shokouhimehr M, Choi Y . Novel production of natural bacteriocin via internalization of dextran nanoparticles into probiotics. Biomaterials. 2019; 218:119360. DOI: 10.1016/j.biomaterials.2019.119360. View